Abstract: A method for fabricating semiconductor devices includes forming channel regions over a substrate. The channel regions, in parallel with one another, extend along a first lateral direction. Each channel region includes at least a respective pair of epitaxial structures. The method includes forming a gate structure over the channel regions, wherein the gate structure extends along a second lateral direction. The method includes removing, through a first etching process, a portion of the gate structure that was disposed over a first one of the channel regions. The method includes removing, through a second etching process, a portion of the first channel region. The second etching process includes one silicon etching process and one silicon oxide deposition process. The method includes removing, through a third etching process controlled based on a pulse signal, a portion of the substrate that was disposed below the removed portion of the first channel region.

Abstract: Embodiments of the invention are directed to computer-implemented methods of analyzing a web-based software application. A non-limiting example of the computer implemented method includes generating, using a processor system, a set of to-be-tested element-event pairs of the web-based software application. A set of compatibility tests is received at the processor system, where the set of compatibility tests is operable to perform compatibility testing of a corresponding set of element-event pairs. A comparison is performed between the set of to-be-tested element-event pairs and the corresponding set of element-event pairs. A compatibility testing recommendation is generated based at least in part on a result of the comparison.

Abstract: The invention provides anti-CaENO1 antibodies and humanized antibodies as effective diagnostic agent or therapeutic treatment against infections caused by Candida spp. (preferably Candida. albicans, Candida tropicalis), fluconazole resistance Candida spp., Streptococcus, or Staphylococcus.

Abstract: The invention provides anti-CaENO1 antibodies and humanized antibodies as effective diagnostic agent or therapeutic treatment against infections caused by Candida spp. (preferably Candida. albicans, Candida tropicalis), fluconazole resistance Candida spp., Streptococcus, or Staphylococcus.

Abstract: Anti-CaENO1 antibodies and humanized antibodies are provided as an effective diagnostic agent or a therapeutic treatment against infections caused by Candida spp., preferably Candida albicans, Candida tropicalis, fluconazole resistance Candida spp., Streptococcus, Staphylococcus.

Abstract: The invention describes an expression factor and methods for inhibiting the growth of cells, for enhancing the activity of a drug, and for inhibiting the virulence of microbes. Methods of screening for expression factor inhibitors are also described. The compositions comprise at least one expression factor inhibitor and may further comprise at least one drug.

Abstract: The invention describes an expression factor and methods for inhibiting the growth of cells, for enhancing the activity of a drug, and for inhibiting the virulence of microbes. Methods of screening for expression factor inhibitors are also described. The compositions comprise at least one expression factor inhibitor and may further comprise at least one drug.